Dr. Gabriel Etienne - CML - Chronic myeloid leukemia
Hématologue Institut Bergonié - Bordeaux
ARTICLES
Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
2016, Journal Blood
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
2016, Journal Blood
Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge
2016, Journal Blood
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
2016, Journal Blood